What Researchers Did
Researchers conducted a review to summarize the incidence, pathogenesis, and current management strategies for haemorrhagic cystitis (HC).
What They Found
They found that HC, characterized by persistent haematuria and lower urinary tract symptoms following radiotherapy or chemotherapy, has a poorly understood pathogenesis and no standard of care. Existing strategies such as fulguration, hyperbaric oxygen therapy, and botulinum toxin A have demonstrated short-term efficacy in cohort studies, while novel agents like liposomal tacrolimus show promise for future research.
What This Means for Canadian Patients
Canadian patients experiencing haemorrhagic cystitis after cancer treatment may find relief from various existing management strategies, even though a standard of care is not yet established. Discussing options like hyperbaric oxygen therapy or intravesical treatments with their healthcare providers could help manage symptoms and improve their quality of life.
Canadian Relevance
This review does not have a direct Canadian connection.
Study Limitations
As a review, this study's findings are limited by the quality and heterogeneity of the existing literature on haemorrhagic cystitis management strategies.